Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Venaxis, Inc. to Webcast Live at RetailInvestorConferences.com on February 7, 2013



Venaxis, Inc. to Webcast Live at RetailInvestorConferences.com on February 7,
                                     2013

Company Invites Main Street and Wall Street Investors to Attend Interactive
Real-time Virtual Conference

PR Newswire

CASTLE ROCK, Colo., Feb. 4, 2013

CASTLE ROCK, Colo., Feb. 4, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY),
an in vitro diagnostic company focused on obtaining FDA clearance and
commercializing its blood-based appendicitis test, APPY1, today announced that
Steve Lundy, President and Chief Executive Officer, will present at
RetailInvestorConferences.com.

DATE: February 7, 2013
TIME: 10:00 AM EST
LINK: www.retailinvestorconferences.com > Click red "register / watch event
      now" button

This will be a live, interactive online event where investors are invited to
ask the company questions in real-time, both in the presentation hall as well
as the company's "virtual trade booth."  If attendees are not able to join the
event live on the day of the conference, an on-demand archive will be
available for 90 days.

It is recommended that investors pre-register to save time and receive event
updates.

About Venaxis, Inc.

Venaxis, Inc. is an in vitro diagnostic company focused on the clinical
development and commercialization of its blood-based appendicitis test,
APPY1.  The unique appendicitis test has projected high sensitivity and
negative predictive value and is designed to aid in the identification of
patients at low risk for acute appendicitis, allowing for more conservative
patient management.  APPY1 is being developed initially for pediatric,
adolescent and young adult patients with abdominal pain, as this population is
at the highest risk for appendicitis and has the highest risk of long-term
health effects associated with CT imaging.  For more information, visit
www.venaxis.com.

About RetailInvestorConferences.com:

Since 2010, RetailInvestorConferences.com has been the only monthly virtual
investor conference series that provides an interactive forum for presenting
companies to meet directly with retail investors using a graphically-enhanced
online platform.

Designed to replicate the look and feel of location-based investor
conferences, Retail Investor Conferences unites PR Newswire's leading-edge
online conferencing and investor communications capabilities with
BetterInvesting's extensive retail investor audience network.

Forward-Looking Statements

This press release includes "forward-looking statements" of Venaxis, Inc.
("Venaxis") (formerly AspenBio Pharma, Inc.) as defined by the Securities and
Exchange Commission ("SEC"). All statements, other than statements of
historical fact, included in this press release that address activities,
events or developments that Venaxis believes or anticipates will or may occur
in the future are forward-looking statements. These statements are based on
certain assumptions made based on experience, expected future developments and
other factors Venaxis believes are appropriate in the circumstances. Such
statements are subject to a number of assumptions, risks and uncertainties,
many of which are beyond the control of Venaxis. Investors are cautioned that
any such statements are not guarantees of future performance. Actual results
or developments may differ materially from those projected in the
forward-looking statements as a result of many factors, including our ability
to successfully complete required product development and modifications in a
timely and cost effective manner, complete clinical trial activities for APPY1
required for FDA submission, obtain FDA clearance or approval, complete and
maintain CE Marking, cost effectively manufacture and generate revenues from
APPY1, execute agreements required to successfully advance the company's
objectives, retain the management team to advance the products, overcome
adverse changes in market conditions and the regulatory environment, obtain
and enforce intellectual property rights, and realize value of intangible
assets. Furthermore, Venaxis does not intend (and is not obligated) to update
publicly any forward-looking statements. The contents of this press release
should be considered in conjunction with the risk factors contained in
Venaxis' recent filings with the SEC, including its Form 10-Q for the period
ended September 30, 2012, filed on November 7, 2012.

SOURCE Venaxis, Inc.

Website: http://www.venaxis.com
Contact: Venaxis, Inc. - For Investors & Media - Joshua Drumm, PhD,
jdrumm@tiberend.com, or Jason Rando, jrando@tiberend.com, both of Tiberend
Strategic Advisors, Inc., +1-212-827-0020; RetailInvestorConferences.com -
Bradley H. Smith, bradley.smith@prnewswire.com, +1-201-942-7157
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement